

## **Our Position on Global Access**

At Vertex, we research, discover and develop innovative medicines for serious diseases. To develop these medicines, we invest significantly in research and development, with the majority of operating expenses and three out of five employees dedicated to that purpose.

Our goal is to make our CF medicines available to as many people with CF as possible around the world. Achieving sustainable access is highly complex and requires many stakeholders to work together. Our teams continue to work creatively and flexibly with government agencies, policymakers, patient advocacy organizations and health insurers every day to expand access, and we have made substantial progress to date. Today, nearly all patients eligible to be treated with a Vertex medicine in North America, Europe, Australia and New Zealand have reimbursed access.

In the U.S., our CF medicines are broadly reimbursed, with more than 99 percent of eligible patients having access through public and private insurance. Our assistance program, Vertex GPS™: Guidance & Patient Support, is available to eligible patients who need assistance navigating insurance coverage and available forms of financial assistance and provides free medicine to patients who do not have insurance and meet certain criteria. We understand health care costs are a concern for every family, especially those who are managing a chronic condition like CF.

We remain focused on expanding access to our medicines geographically, as well as to younger and broader populations. At the end of 2022, our medicines were reimbursed or accessible to patients in more than 60 countries through more than 40 reimbursement agreements and other forms of access. Because of our commitment to ensuring that our medicines reach patients as quickly as possible, most of the signed reimbursement or access agreements for our newest CF medicine have been secured more quickly than industry averages.

In countries where there is a path for sustainable access, we've offered compassionate use programs for our CF medicines to help those who are critically ill and can't wait until formal agreements are in place. We recognize that there are people with CF who could benefit from our medicines but who live in countries where access challenges are significant due to economic constraints or inadequate health care infrastructure. In such countries, we are actively evaluating options that may facilitate access to our medicines. As an example, we have initiated a pilot program to provide our medicines at no cost to people with CF in 12 lower-income countries on four continents.

While we've made significant progress, we know there is more to do. Our teams are working every day to expand access and to make our medicines accessible to more people with CF around the world.